People and Business: On the move

Click to follow
The Independent Online
DR DAVID U'PRICHARD, who stepped down as chairman of research and development at SmithKline Beecham recently after only 18 months in the job, has popped up as a non-executive director of RiboTargets, a Cambridge-based biotechnology company.

Dr U'Prichard, 50, was international research director at Zeneca Pharmaceuticals between 1994 and 1997, when he moved to SmithKline Beecham.

RiboTargets was formed in July 1997 to commercialise revolutionary developments in the understanding of RNA, the link between the genetic information contained in DNA and protein synthesis.

The company is involved in developing a range of drugs to combat HIV and Hepatitis C.